Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...

LOUISVILLE, Ky. -- Minimally invasive ablative therapy for early kidney cancer had an increased risk of local and metastatic ...

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

A discussion of these statements and risk factors is available on the current safe harbor ... where our STARS Safety Abstract ...

The study examined how users that are part of the site’s self-harm, self-help community use it to get mental health help and support.

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

For high-net-worth individuals, financing a home purchase isn’t just about affording the property but optimizing financial ...

Pharmacokinetic Results: TX45 demonstrated a potential best-in-class half-life for a long-acting relaxin therapy. Final analysis showed that a single dose of TX45 had approximately 50% subcutaneous ...

"Oh this would absolutely break me," one user said. Another added: "Idk [I don't know] why but this immediately made me burst into tears." ...

The reminders are everywhere. When a woman turns 40, doctors say she should begin receiving yearly mammograms to detect ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...